Details for New Drug Application (NDA): 020559
✉ Email this page to a colleague
The generic ingredient in TRITEC is ranitidine bismuth citrate. There are forty-three drug master file entries for this compound. Additional details are available on the ranitidine bismuth citrate profile page.
Summary for 020559
Tradename: | TRITEC |
Applicant: | Glaxosmithkline |
Ingredient: | ranitidine bismuth citrate |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 400MG | ||||
Approval Date: | Aug 8, 1996 | TE: | RLD: | No |
Expired US Patents for NDA 020559
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription